Primary Job Title Founder, President & CSO Primary Organization Nirogy Therapeutics
Location Greater Boston Area, United States, North America Regions East Coast, New England Gender Male
LinkedIn View on LinkedIn
Prior to Nirogy, Vincent was the Senior Director at Karyopharm where he discovered the drug, XPOVIO® (Selinexor) currently approved for multiple myeloma and lymphoma indications. Dr. Sandanayaka began his career at Pfizer and moved through the ranks with increasing responsibility at AstraZeneca, DeCode Genetics/Amgen, Epix Pharmaceuticals, and
Karyopharm. His efforts led to six novel compounds that were investigated in clinical trials spanning immunology, cardiovascular, neuroscience, and oncology therapeutic areas.
Vincent completed a post-doctoral fellowship at Emory University, obtained Ph.D. in Synthetic Organic Chemistry from Wayne State University, and holds a B.Sc (Special) degree from the University of Peradeniya, Sri Lanka.
